The end of dual therapy with renin-angiotensin-aldosterone system blockade?

New England Journal of Medicine

Volumn 369, Issue 20, 2013, Pages 1960-1962

  De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; EARLY TERMINATION OF CLINICAL TRIAL; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MACROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RISK REDUCTION;

EID: 84887482009     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1312286     Document Type: Editorial

References (11)

1. Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536-50.
2. de Zeeuw D. Unmet need in renal protection - do we need a more comprehensive approach? Contrib Nephrol 2011;171:157-60.
3. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 2013;26:424-41.
4. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
5. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
6. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
7. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903.
8. Miao Y, Dobre D, Heerspink HJ, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011;54:44-50. [Erratum, Diabetologia 2011;54:2209.]
9. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360.
10. Study Of Diabetic Nephropathy With Atrasentan (SONAR). ClinicalTrials.gov no. NCT01858532 (http://clinicaltrials.gov/ct2/show/NCT01858532).
11. Smink PA, Miao Y, Eijkemans MJ, et al. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2013 September 25 (Epub ahead of print).